valsartan and nephrin
valsartan has been researched along with nephrin in 10 studies
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bonnet, F; Burns, WC; Candido, R; Cao, Z; Carey, RM; Cooper, ME; De Gasparo, M; Kawachi, H; Nesteroff, SP; Shimizu, F | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H | 1 |
| Iigaya, K; Kumagai, H; Onami, T; Saruta, T; Takimoto, C | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, HY; Zhang, Y | 1 |
| Border, WA; Cheung, AK; Gu, C; Huang, Y; Noble, NA; Zhou, G | 1 |
| Guan, G; Li, P; Lv, W; Qi, D; Wang, J; Zhang, Y | 1 |
| Cheung, AK; Huang, Y; Liu, X; Zhou, G | 1 |
| Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X | 1 |
| Guo, F; Huang, F; Ma, X; Qin, G; Wang, Q; Wu, L | 1 |
| Liu, ZY; Shan, C; Wu, H; Yu, J; Zhang, KQ; Zhu, Q | 1 |
Reviews
1 review(s) available for valsartan and nephrin
| Article | Year |
|---|---|
[Molecular mechanisms underlying proteinuria reduction and protection of nephrin and podocytes by ARB].
Topics: Actinin; Actins; Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cytoskeletal Proteins; Humans; Intracellular Signaling Peptides and Proteins; Kidney Failure, Chronic; Membrane Proteins; Podocytes; Proteins; Proteinuria; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2006 |
Other Studies
9 other study(ies) available for valsartan and nephrin
| Article | Year |
|---|---|
Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cytoprotection; Diuresis; Gene Expression; Imidazoles; Kidney; Kidney Diseases; Male; Membrane Proteins; Nephrectomy; Organ Size; Proteins; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Kidney Glomerulus; Male; Membrane Proteins; Proteins; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sclerosis; Systole; Tetrazoles; Valine; Valsartan; Verapamil | 2003 |
Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Topics: Animals; Chemokine CCL2; Desmin; Diabetic Nephropathies; Drug Therapy, Combination; Immunohistochemistry; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2007 |
Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Glomerulonephritis; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Function Tests; Male; Membrane Proteins; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2014 |
Mycophenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Diabetes Mellitus, Experimental; Kidney; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan; WT1 Proteins | 2013 |
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins | 2014 |
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan inhibits amylin-induced podocyte damage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blotting, Western; Cell Line; Cytoprotection; Desmin; Fluorescent Antibody Technique; Intracellular Signaling Peptides and Proteins; Islet Amyloid Polypeptide; Male; Membrane Proteins; Mice; Microscopy, Electron, Transmission; Podocytes; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Valsartan | 2016 |
Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Chemokine CXCL9; Diabetic Nephropathies; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Membrane Proteins; Mice; Podocytes; Proto-Oncogene Proteins c-bcl-2; Receptors, Angiotensin; Receptors, CXCR3; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Tyrphostins; Valsartan | 2017 |